CSDR Expands Access to Data from 3,460 Clinical Trials
BOSTON--(BUSINESS WIRE)-ClinicalStudyDataRequest.com (CSDR), a cross-industry initiative providing researchers with access to clinical trial data from 13 major pharmaceutical companies, including trials that involve multiple sponsors, has increased the number of trials available to more than 3,460.
The available trials span all major disease areas. For example, there are over 360 diabetes and 240 asthma trials listed. Since the initiative was launched, there have been 335 requests from researchers for trial data.
CSDR offers medical and scientific researchers an array of clinical trial data to facilitate collaboration, advance scientific knowledge, and improve outcomes for patients. Through this portal, researchers can request anonymized patient-level data from the list of clinical trials via an independent process managed by the Wellcome Trust.
“CSDR is proud to have reached these important milestones toward our goal of promoting scientific research by giving access to detailed, patient-level data. We are increasing the number of trials listed and making it easier to access the data. A further critical step this fall will be the unveiling of an enhanced web portal for researchers,” said Scott Martin, chair of the ClinicalStudyDataRequest.com Steering Committee.
Contact
KMR Group
Scott Martin
312.795.0400
smartin@kmrgroup.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
